AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases (IMAGE)

InSilico Medicine

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

Caption

  • Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's annual pipeline output efficiency.
  • AI-Enabled Molecular Glue Design for Undruggable Targets: Designed and optimized with AI, ISM9546 features a peripherally restricted profile that reduces central nervous system (CNS) risks through minimal brain exposure, while demonstrating favorable tolerability and broad safety margins.
  • Robust Preclinical Efficacy: ISM9546 demonstrated sub-nanomolar degradation potency in cellular assays and achieved a significant reduction in Disease Activity Index (DAI) within days of treatment in disease models; histopathological analysis further confirmed its anti-inflammatory effects, reducing pathology scores by approximately 60%.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.